title: ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
abstract: OBJECTIVE
  The purpose of the present study was to investigate the possible association between Excision repair cross-complementing group 1 (ERCC1) score and platinum resistance in first-line chemotherapy for ovarian cancer.
  
  
  METHODS
  ERCC1 Expression was determined using immunohisto-chemistry in 68 patients with platinum-responding tumor and 30 with platinum-resistant tumors. The primary end-point of this study was the association between the expression of ERCC1 protein with resistance to standard platinum-based chemotherapy in primary ovarian cancer.
  
  
  RESULTS
  In pairwise comparisons, the overall survival (OS) for patients with ovarian cancer, who were non-responders to platinum-based chemotherapy with low or intermediate H-score for ERCC1 was better than that of non-responders with high H-score for ERCC1 [median OS=21 (16.8-25.2 months) and 28 (14.6-41.4 months) vs. 15 months (6.2-23.8 months), p-value=0.048, and p-value=0.017, respectively].
  
  
  CONCLUSIONS
  There were no significant differences in the progression-free survival between those with low, intermediate and high H-score for ERCC1. There is no statistically significant relationship between ERCC1 score and response to platinum-based chemotherapy in patients with primary ovarian cancer.
authors.affiliation: University Medicine of Berlin, Charité/Campus Virchow, Augustenburger Platz 1, 13353 Berlin, Germany. Mustafa-Zelal.Muallem@charite.de.
authors.forename: Mustafa Zelal
authors.initials: MZ
authors.lastname: Muallem
authors.forename: Ioana
authors.initials: I
authors.lastname: Braicu
authors.forename: Mani
authors.initials: M
authors.lastname: Nassir
authors.forename: Rolf
authors.initials: R
authors.lastname: Richter
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
authors.forename: Ruza
authors.initials: R
authors.lastname: Arsenic
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016190:Carboplatin / Q000008:administration & dosage; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D002945:Cisplatin / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D004720:Endonucleases / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D016190:Carboplatin; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin
keywords: ERCC1 expression; Epithelial ovarian cancer; immunohistochemistry staining; platinum based chemotherapy